BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO)

Historical Holders from Q2 2019 to Q4 2025

Type / Class: Equity / Common Stock, par value $0.001 per share
Symbol: BBIO on Nasdaq
Shares outstanding: 193,828,463
Price per share: $76.49
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares as of 30 Sep 2025: 184,960,254
Total reported value: $9,606,772,497
% of total 13F portfolios: 0.02%
Share change: -3,594,507
Value change: -$158,354,676
Avg buy value change: +0%
Avg sell value change: -0%
Number of holders: 387
Price from insider filings: $75.24

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
VANGUARD GROUP INC	8.7%		$574,501,727		16,484,985		The Vanguard Group	30 Jun 2025
VIKING GLOBAL INVESTORS LP	8.2%	-15%	$825,530,932	-$140,704,733	15,893,934	-15%	VIKING GLOBAL INVESTORS LP	14 Nov 2025
KKR Genetic Disorder L.P.	7%	-31%	$436,020,726	-$197,280,000	13,260,971	-31%	KKR Genetic Disorder L.P.	12 May 2025
Kumar Neil	5.4%		$344,145,491		10,466,712		NEIL KUMAR	31 Dec 2024

As of 30 Sep 2025, BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) has 387 institutional shareholders filing 13F forms. They hold 184,960,254 shares. of 193,828,463 outstanding shares (95%) .

Top 25 institutional shareholders own 66% of the company.

Filer	Ownership	Nb Shares	Share Change %	Portfolio %	Holdings Value
VANGUARD GROUP INC	8.7%	16,832,059	+2.1%	0.01%	$874,257,145
VIKING GLOBAL INVESTORS LP	8.2%	15,977,849	-14%	2.2%	$829,889,477
BlackRock, Inc.	7.4%	14,411,203	+1.1%	0.01%	$748,517,884
Kohlberg Kravis Roberts & Co. L.P.	6.8%	13,260,971	0%	12%	$688,774,834
JANUS HENDERSON GROUP PLC	4.5%	8,741,079	-5.8%	0.21%	$453,956,601
FARALLON CAPITAL MANAGEMENT LLC	4.2%	8,192,000	+3.7%	2.4%	$425,492,480
Aisling Capital Management LP	3.1%	6,089,611	+0.35%	69%	$316,294,395
STATE STREET CORP	2.9%	5,606,340	-4.9%	0.01%	$291,193,300
Invesco Ltd.	2%	3,928,657	+40%	0.03%	$204,054,444
GEODE CAPITAL MANAGEMENT, LLC	2%	3,909,941	+6.2%	0.01%	$203,113,418
Frazier Life Sciences Management, L.P.	2%	3,845,457	+1.2%	6%	$199,733,037
UBS Group AG	1.3%	2,586,422	-8%	0.03%	$134,338,759
TWO SIGMA INVESTMENTS, LP	1.2%	2,328,941	-0.43%	0.19%	$120,965,196
ALLIANCEBERNSTEIN L.P.	1.2%	2,328,715	-5.7%	0.04%	$120,953,457
D. E. Shaw & Co., Inc.	1.2%	2,252,762	+8.2%	0.09%	$117,008,458
GOLDMAN SACHS GROUP INC	1.1%	2,209,159	-16%	0.02%	$114,743,718
Capital Research Global Investors	1%	1,933,126	-52%	0.02%	$100,406,564
MACQUARIE GROUP LTD	1%	1,933,096	-7.7%	0.12%	$100,405,000
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	0.99%	1,925,198	+45%	0.02%	$99,994,784
MANUFACTURERS LIFE INSURANCE COMPANY, THE	0.99%	1,914,767	+1.2%	0.08%	$99,452,998
SC US (TTGP), LTD.	0.96%	1,860,364	0%	0.6%	$96,627,306
Laurion Capital Management LP	0.9%	1,753,544	-27%	12%	$91,079,076
FMR LLC	0.88%	1,700,747	-16%	0%	$88,336,805
TWO SIGMA ADVISERS, LP	0.86%	1,662,755	-1.3%	0.17%	$86,363,495
Driehaus Capital Management LLC	0.86%	1,662,069	-1.7%	0.62%	$86,327,864

Institutional Holders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (% of par)	Investors
2025 Q4	168,944	$12,911,062	-$11,894,619			7,649%	9
2025 Q3	184,960,254	$9,606,772,497	-$158,354,676	$95,310,452	$585,114,262	5,194%	387
2025 Q2	188,818,044	$8,154,464,813	+$171,957,147	$95,078,274	$485,218,066	4,318%	357
2025 Q1	185,173,982	$6,405,659,795	+$325,204,584	$72,291,862	$441,052,155	3,457%	302
2024 Q4	176,660,902	$4,847,588,352	+$119,458,488	$68,033,556	$354,464,324	2,744%	260
2024 Q3	171,443,774	$4,364,456,677	-$97,308,884	$60,246,408	$264,161,420	2,546%	256
2024 Q2	174,823,558	$4,428,264,206	+$85,659,512	$69,984,256	$216,720,947	2,533%	252
2024 Q1	170,429,536	$5,269,328,955	+$130,075,277	$79,223,644	$230,753,268	3,092%	245
2023 Q4	350,754	$14,281,223	+$8,118,476			4,037%	3
2023 Q3	160,532,170	$4,228,630,384	+$311,467,959	$42,848,613	$52,895,583	2,637%	216
2023 Q2	148,984,497	$2,562,058,177	-$53,835,959	$73,921,250	$98,916,758	1,720%	194
2023 Q1	152,299,858	$2,524,898,700	+$153,216,330	$27,818,632	$38,811,646	1,658%	208
2022 Q4	144,543,586	$1,101,392,226	-$14,635,108	$443,484	$1,069,396	762%	173
2022 Q3	145,168,440	$1,443,104,342	+$49,016,089	$1,749,000	$1,947,000	994%	167
2022 Q2	138,095,961	$1,253,730,611	-$25,389,349	$2,645,000	$5,804,000	907.99%	149
2022 Q1	140,942,218	$1,430,811,689	-$30,306,744	$3,799,000	$7,253,000	1,015%	163
2021 Q4	141,450,137	$2,358,480,554	-$120,474,242	$62,930,308	$108,959,716	1,668%	177
2021 Q3	139,971,233	$6,561,165,282	-$164,818,106	$36,517,500	$18,785,000	4,686.93%	206
2021 Q2	142,537,078	$8,688,688,164	+$97,051,829	$43,272,000	$18,241,000	6,095.99%	196
2021 Q1	141,008,716	$8,684,417,555	+$1,240,009,474	$38,743,000	$18,312,000	6,160%	196
2020 Q4	120,722,579	$8,584,366,232	+$180,150,479	$8,027,000	$23,212,000	7,110.99%	158
2020 Q3	117,771,063	$4,390,789,630	+$21,690,562	$1,658,000	$1,727,000	3,752%	124
2020 Q2	117,243,177	$3,822,802,476	+$145,764,061	$558,000	$23,654,000	3,260.99%	113
2020 Q1	112,837,365	$3,272,259,195	+$162,723,850	$1,760,000	$10,074,000	2,900%	92
2019 Q4	99,870,663	$3,500,465,628	+$147,814,760			3,505%	83
2019 Q3	103,219,922	$2,216,104,734	+$110,359,965			2,146.99%	73
2019 Q2	99,927,998	$2,695,534,750	+$2,695,535,120			2,697%	60